Pruski Dominik, Łagiedo-Żelazowska Małgorzata, Millert-Kalińska Sonja, Sikora Jan, Jach Robert, Przybylski Marcin
Department of Obstetrics and Gynecology, District Public Hospital in Poznan, 60-479 Poznań, Poland.
Gynecology Specialised Practise, 60-408 Poznań, Poland.
Vaccines (Basel). 2022 May 6;10(5):728. doi: 10.3390/vaccines10050728.
Vaccinations against human papillomavirus (HPV) are included in the primary prevention of precancerous intraepithelial lesions and HPV-related cancers. Despite the undeniable effectiveness of vaccination in the juvenile population, there is still little research on the effect in patients after sexual initiation. Our study aims to assess anti-HPV (L1 HPV) antibodies in healthy patients and diagnosed cervical pathology after 9-valent vaccination. We provide a prospective, ongoing 12-month, non-randomised pilot study in which 89 subjects were enrolled. We used an enzyme-linked immunosorbent assay to determine IgG class antibodies to HPV. We noted significantly higher levels of antibodies in vaccinated individuals than in the unvaccinated control group. The above work shows that vaccination against HPV might be beneficial in patients after sexual initiation as well as in those already diagnosed with HPV or SIL infection.
人乳头瘤病毒（HPV）疫苗接种属于癌前上皮内病变和HPV相关癌症一级预防的范畴。尽管疫苗接种在青少年人群中的有效性无可否认，但对于性成熟后患者疫苗接种效果的研究仍然较少。我们的研究旨在评估9价疫苗接种后健康患者和已诊断宫颈病变患者体内的抗HPV（L1型HPV）抗体。我们开展了一项前瞻性、为期12个月的非随机试点研究，招募了89名受试者。我们采用酶联免疫吸附测定法来测定HPV的IgG类抗体。我们注意到，接种疫苗个体的抗体水平显著高于未接种疫苗的对照组。上述研究表明，HPV疫苗接种对于性成熟后的患者以及已诊断为HPV或SIL感染的患者可能同样有益。
